Trial Profile
Post-Licensure Safety Study of ISENTRESS in a US Managed Care Network
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 27 Oct 2018 Results published in the HIV Clinical Trials
- 06 Apr 2016 Number of groups changed from 3 to 7 in treatment table, Time frame for primary endpoint changed (January 2000 - December 2014 to Historical Cohort: up to 33 months (January 2005 to October 2007); Raltegravir and Concurrent Cohorts: up to 69 months (October 2007 to June 2013))
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.